Although the primary outcome measure did not reach statistical significance ( p = 0.35), several secondary measures showed significant results: MCS #1 triggering of cramps ( p = 0.01), MCS #2 cramp frequency ( p = 0.03), MCS Additional 1 change of motor behaviors ( p = 0.02), and CGIC assessed by the evaluator ( p = 0.009).
← all excerpts
Placebo-Controlled, Randomized Double-Blind N-Of-1 Trial to Study Safety and Potential Efficacy of TJ-68 for Improving Muscle Cramps in Patients With Amyotrophic Lateral Sclerosis: A Pilot Study.
1
0.3500
0.3500